103 related articles for article (PubMed ID: 11074613)
21. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
[TBL] [Abstract][Full Text] [Related]
22. New markers and multivariate models for prostate cancer detection.
Stephan C; Rittenhouse H; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
Anticancer Res; 2009 Jul; 29(7):2589-600. PubMed ID: 19596933
[TBL] [Abstract][Full Text] [Related]
23. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
24. Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer.
Lange PH; Brawer MK
Urology; 1989 Jun; 33(6 Suppl):13-7. PubMed ID: 2471346
[No Abstract] [Full Text] [Related]
25. [Prostate cancer].
Uchida K; Akaza H
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
[TBL] [Abstract][Full Text] [Related]
26. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
27. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract][Full Text] [Related]
28. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
29. [Tumor markers of urinary tract carcinoma].
Kikuchi H
Rinsho Byori; 2004 Apr; 52(4):371-80. PubMed ID: 15164607
[TBL] [Abstract][Full Text] [Related]
30. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract][Full Text] [Related]
31. [Clinical surveillance after surgery for prostate cancer].
Guercio S; Terrone C; Scarpa RM
Recenti Prog Med; 2003 Mar; 94(3):110-3. PubMed ID: 12677777
[TBL] [Abstract][Full Text] [Related]
32. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
33. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
34. Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers.
Lukyanchuk VV; Friess H; Kleeff J; Osinsky SP; Ayuni E; Candinas D; Roggo A
Anticancer Res; 2003; 23(3B):2711-6. PubMed ID: 12894563
[TBL] [Abstract][Full Text] [Related]
35. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
36. Beyond prostate-specific antigen: alternate serum markers.
RamÃrez ML; Nelson EC; Evans CP
Prostate Cancer Prostatic Dis; 2008; 11(3):216-29. PubMed ID: 18227856
[TBL] [Abstract][Full Text] [Related]
37. [The search for better markers for prostate cancer than prostate-specific antigen].
Schenk-Braat EA; Bangma CH
Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
[TBL] [Abstract][Full Text] [Related]
38. Measurement of prostate-specific antigen as a screening test for prostate cancer.
N Engl J Med; 1991 Sep; 325(13):963-5. PubMed ID: 1715514
[No Abstract] [Full Text] [Related]
39. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
Stephan C; Cammann H; Meyer HA; Lein M; Jung K
Cancer Lett; 2007 Apr; 249(1):18-29. PubMed ID: 17292541
[TBL] [Abstract][Full Text] [Related]
40. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
